
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TOP-N53
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Details : TOP-N53 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scleroderma, Systemic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 01, 2025
Lead Product(s) : TOP-N53
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
